Vera Therapeutics, Inc. financial data

Symbol
VERA on Nasdaq
Location
Brisbane, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1603% % -26%
Debt-to-equity 22% % 14%
Return On Equity -60% % -52%
Return On Assets -49% % -49%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 63,928,066 shares 0.96%
Entity Public Float $1,300,000,000 USD -24%
Common Stock, Value, Issued $71,000 USD 11%
Weighted Average Number of Shares Outstanding, Basic 64,233,814 shares 16%
Weighted Average Number of Shares Outstanding, Diluted 64,233,814 shares 16%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $215,256,000 USD 71%
General and Administrative Expense $100,217,000 USD 144%
Operating Income (Loss) $315,473,000 USD -89%
Nonoperating Income (Expense) $15,859,000 USD 5.6%
Net Income (Loss) Attributable to Parent $299,615,000 USD -97%
Earnings Per Share, Basic -4.66 USD/shares -69%
Earnings Per Share, Diluted -4.66 USD/shares -69%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $354,725,000 USD 283%
Marketable Securities, Current $359,864,000 USD -34%
Other Assets, Current $2,535,000 USD 83%
Assets, Current $728,883,000 USD 12%
Property, Plant and Equipment, Net $1,374,000 USD 43%
Operating Lease, Right-of-Use Asset $1,923,000 USD -43%
Assets $734,733,000 USD 12%
Accounts Payable, Current $21,898,000 USD 186%
Employee-related Liabilities, Current $18,700,000 USD 174%
Accrued Liabilities, Current $31,008,000 USD 91%
Liabilities, Current $53,455,000 USD 111%
Operating Lease, Liability, Noncurrent $1,919,000 USD -22%
Liabilities $130,212,000 USD 66%
Accumulated Other Comprehensive Income (Loss), Net of Tax $786,000 USD 100%
Retained Earnings (Accumulated Deficit) $760,865,000 USD -65%
Stockholders' Equity Attributable to Parent $604,521,000 USD 4.7%
Liabilities and Equity $734,733,000 USD 12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $54,406,000 USD -61%
Net Cash Provided by (Used in) Financing Activities $1,533,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $15,317,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $37,556,000 USD -260%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $354,725,000 USD 283%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,581,000 USD 4%
Deferred Tax Assets, Valuation Allowance $172,267,000 USD 61%
Deferred Tax Assets, Gross $172,839,000 USD 61%
Operating Lease, Liability $2,468,000 USD -38%
Payments to Acquire Property, Plant, and Equipment $187,000 USD
Lessee, Operating Lease, Liability, to be Paid $3,045,000 USD -43%
Operating Lease, Liability, Current $549,000 USD -63%
Lessee, Operating Lease, Liability, to be Paid, Year Two $966,000 USD 16%
Lessee, Operating Lease, Liability, to be Paid, Year One $830,000 USD -64%
Operating Lease, Weighted Average Discount Rate, Percent 0.125 pure 11%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $577,000 USD -58%
Lessee, Operating Lease, Liability, to be Paid, Year Three $995,000 USD 3%
Deferred Tax Assets, Operating Loss Carryforwards $84,624,000 USD 118%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $2,646,000 USD 29%
Lessee, Operating Lease, Liability, to be Paid, Year Four $254,000 USD -74%
Operating Lease, Payments $634,000 USD -17%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $85,000 USD 673%
Deferred Tax Assets, Net of Valuation Allowance $572,000 USD -28%
Share-based Payment Arrangement, Expense $37,926,000 USD 82%
Interest Expense $5,816,000 USD 130%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%